A Phase 3 interventional study of Arimoclomol and Placebo in Amyotrophic Lateral Sclerosis, sponsored by ZevraDenmark. Completed at 29 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-08-24.
Sponsored by ZevraDenmark · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 440 studies in Amyotrophic Lateral Sclerosis with a site in United States — 98 open to participants now, 129 under way, 11 of them phase 3. Amyotrophic Lateral Sclerosis · United States.
Among the 440 studies in Amyotrophic Lateral Sclerosis with a site in United States, this one is the 35th largest by enrollment of the 307 interventional ones that give a count, is one of 20 that started in 2018, is one of 30 in phase 3, and was the 213th registered.
981 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 280 are open to participants now.
Browse Amyotrophic Lateral Sclerosis studies →98 of the 440 studies in Amyotrophic Lateral Sclerosis with a site in United States are open now. Recruiting first, the newest first:
Johns Hopkins University · Sites in United States
Ages 18–80
Cognixion · Sites in United States
Ages 18+
Johns Hopkins University · Sites in United States
Ages 18+ · Healthy volunteers
Neuralink Corp · Sites in United States
Ages 18+
Biogen · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 194 Amyotrophic Lateral Sclerosis studies recruiting now, 119 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 56 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
440 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 89 · Phase 2 139 · Phase 3 48 · Phase 4 1
First in 1982; this study’s year is marked. 20 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 245 is above the median of 38 across 664 interventional studies indexed under Amyotrophic Lateral Sclerosis.
Median enrollment 33 across the 307 interventional studies, 100 across the 121 observational. Of the 277 that completed or were terminated, 102 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
163 of 440 have an industry lead sponsor. The 10 most frequent:
ZevraDenmark is the lead sponsor of 8 studies on the registry; 1 is open to participants now.
ZevraDenmark has 2 studies filed under Amyotrophic Lateral Sclerosis — fewer than ten, so there is no comparison to draw.
41 of the studies in Amyotrophic Lateral Sclerosis with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07161999Phase 3Coya TherapeuticsStudy of COYA 302 for the Treatment of ALS | 2027-04 |
| NCT04057898Phase 3MediciNovaEvaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS | 2027-04 |
| NCT04297683Phase 3Merit E. Cudkowicz, MDHEALEY ALS Platform Trial - Master Protocol | 2027-07 |
| NCT07410806Phase 3Merit E. Cudkowicz, MDHEALEY ALS Platform Trial - Regimen I NUZ-001 | 2027-07-01 |
| NCT04220190Phase 3Rapa Therapeutics LLCRAPA-501 Therapy for ALS | 2027-07-01 |
Add all 41 to your calendar (.ics) → With an account.
Among the 440 studies in Amyotrophic Lateral Sclerosis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A multicenter, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy and safety of arimoclomol in amyotropic lateral sclerosis (ALS)
Screening up to 4 weeks Treatment up to 76 weeks
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
248 mg arimoclomol base (equivalent to 400 mg arimoclomol citrate) 3 times daily
Drug: Arimoclomol
248 mg matching placebo 3 times daily
Drug: Placebo
2 capsules (2 x 124 mg arimoclomol base; equivalent to 2 x 200 mg arimoclomol citrate) taken 3 times daily
2 matched placebo capsules taken 3 times daily
Combined Assessment of Function and Survival (CAFS)
Combined Assessment of Function and Survival (CAFS) is a composite endpoint that includes 1) the change from baseline in revised ALS functional rating scale (ALSFRS-R) and 2) the survival endpoint (time to permanent assisted ventilation \[PAV\], tracheostomy or death). On the ALSFRS-R, 12 functions are rated on 5-point ordinal rating scales (from 0 to 4) with a total score range (minimum and maximum score) of 0-48 (sum of all 12 items). The higher the score the better functioning. For the survival endpoint, the longer time to PAV, tracheostomy, or death the better outcome. A patient's CAFS score represents a patient's rank in the study based on comparing the patient's outcome for both the change in ALSFRS-R and the time to event (PAV, tracheostomy, or death) to the outcome for all other patients in the study in a pairwise fashion. A higher rank score (range 0-1) is considered a better outcome. The reported values are the mean rank scores in each group for the composite endpoint.
Time frame: Over 76 Weeks
Time to Permanent Assisted Ventilation (PAV) / Tracheostomy / Death
Time from baseline to one of the events (PAV / tracheostomy / death). PAV is defined as the first of 7 consecutive days on which PAV was used for \>22 hours/day
Time frame: Over 76 weeks
Change From Baseline to Week 76 (or End-of-trial) in the Revised ALS Functional Rating Scale (ALSFRS-R)
The ALSFRS-R score is based on a rating scale where 12 functions are rated on 5-point ordinal rating scales (from 0 to 4) with a maximum score of 48 (sum of all 12 items). The higher the score the better functioning.
Time frame: Week 76 (or end of trial)
Change From Baseline to Week 76 (or End-of-trial) in Percent (%) Predicted Slow Vital Capacity (SVC)
Slow Vital Capacity (SVC) is a measure of breathing function. SVC measures the volume that can be exhaled from a full inhalation after exhaling to a maximum as slowly as possible. The percent (%) of predicted SVC is reported.
Time frame: Week 76 (or end of trial)
| Milestone | Arimoclomol (up to 76 Weeks) | Placebo (up to 76 Weeks) |
|---|---|---|
| Started | 160 | 79 |
| Completed | 122 | 63 |
| Not completed | 38 | 16 |
| Withdrew: Lost to follow-up | 2 | 0 |
| Withdrew: Adverse event | 11 | 1 |
| Withdrew: Physician decision | 3 | 0 |
| Withdrew: Withdrawal by subject | 22 | 15 |
Combined Assessment of Function and Survival (CAFS) is a composite endpoint that includes 1) the change from baseline in revised ALS functional rating scale (ALSFRS-R) and 2) the survival endpoint (time to permanent assisted ventilation \[PAV\], tracheostomy or death). On the ALSFRS-R, 12 functions are rated on 5-point ordinal rating scales (from 0 to 4) with a total score range (minimum and maximum score) of 0-48 (sum of all 12 items). The higher the score the better functioning. For the survival endpoint, the longer time to PAV, tracheostomy, or death the better outcome. A patient's CAFS score represents a patient's rank in the study based on comparing the patient's outcome for both the change in ALSFRS-R and the time to event (PAV, tracheostomy, or death) to the outcome for all other patients in the study in a pairwise fashion. A higher rank score (range 0-1) is considered a better outcome. The reported values are the mean rank scores in each group for the composite endpoint.
| score on a scale | Arimoclomol (up to 76 Weeks) | Placebo (up to 76 Weeks) |
|---|---|---|
| Combined Assessment of Function and Survival (CAFS) | 0.51 ± 0.291 | 0.49 ± 0.283 |
Time from baseline to one of the events (PAV / tracheostomy / death). PAV is defined as the first of 7 consecutive days on which PAV was used for \>22 hours/day
| days | Arimoclomol (up to 76 Weeks) | Placebo (up to 76 Weeks) |
|---|---|---|
| Time to Permanent Assisted Ventilation (PAV) / Tracheostomy / Death | NA (479 to NA) | NA (466 to NA) |
The ALSFRS-R score is based on a rating scale where 12 functions are rated on 5-point ordinal rating scales (from 0 to 4) with a maximum score of 48 (sum of all 12 items). The higher the score the better functioning.
| units on a scale | Arimoclomol (up to 76 Weeks) | Placebo (up to 76 Weeks) |
|---|---|---|
| Change From Baseline to Week 76 (or End-of-trial) in the Revised ALS Functional Rating Scale (ALSFRS-R) | -15.4 ± 8.71 | -15.0 ± 9.10 |
Slow Vital Capacity (SVC) is a measure of breathing function. SVC measures the volume that can be exhaled from a full inhalation after exhaling to a maximum as slowly as possible. The percent (%) of predicted SVC is reported.
| percent (%) predicted SVC | Arimoclomol (up to 76 Weeks) | Placebo (up to 76 Weeks) |
|---|---|---|
| Change From Baseline to Week 76 (or End-of-trial) in Percent (%) Predicted Slow Vital Capacity (SVC) | -30.65 ± 26.346 | -30.38 ± 23.839 |
Collected over From first dose of study medication up to 76 weeks. Assessed every week.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arimoclomol (up to 76 Weeks) | 29/160 (18.1%) | 36/160 (22.5%) | 149/160 (93.1%) |
| Placebo (up to 76 Weeks) | 18/79 (22.8%) | 20/79 (25.3%) | 71/79 (89.9%) |
| Event | Arimoclomol (up to 76 Weeks) | Placebo (up to 76 Weeks) |
|---|---|---|
| PneumoniaInfections and infestations | 4/160 | 5/79 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 7/160 | 2/79 |
| Pneumonia aspirationRespiratory, thoracic and mediastinal disorders | 2/160 | 2/79 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 2/160 | 2/79 |
| Femur fractureInjury, poisoning and procedural complications | 0/160 | 2/79 |
| Deep vein thrombosisVascular disorders | 3/160 | 0/79 |
| StridorRespiratory, thoracic and mediastinal disorders | 0/160 | 1/79 |
| BronchitisInfections and infestations | 0/160 | 1/79 |
| DiverticulitisInfections and infestations | 0/160 | 1/79 |
| InfluenzaInfections and infestations | 0/160 | 1/79 |
| Event | Arimoclomol (up to 76 Weeks) | Placebo (up to 76 Weeks) |
|---|---|---|
| HeadacheNervous system disorders | 34/160 | 21/79 |
| FallInjury, poisoning and procedural complications | 33/160 | 17/79 |
| ConstipationGastrointestinal disorders | 32/160 | 10/79 |
| NasopharyngitisInfections and infestations | 14/160 | 15/79 |
| NauseaGastrointestinal disorders | 27/160 | 3/79 |
| InsomniaPsychiatric disorders | 23/160 | 7/79 |
| DiarrhoeaGastrointestinal disorders | 16/160 | 8/79 |
| DizzinessNervous system disorders | 16/160 | 4/79 |
| Oedema peripheralGeneral disorders | 15/160 | 5/79 |
| Back painMusculoskeletal and connective tissue disorders | 14/160 | 7/79 |
All participants in the modified intention-to-treat (mITT) population
| Age, Continuous(years) | Arimoclomol (up to 76 Weeks) | Placebo (up to 76 Weeks) | Total |
|---|---|---|---|
| Mean | 58.0 ± 11.26 | 56.6 ± 9.97 | 57.6 ± 10.85 |
| Sex: Female, Male(Participants) | Arimoclomol (up to 76 Weeks) | Placebo (up to 76 Weeks) | Total |
|---|---|---|---|
| Female | 54 | 34 | 88 |
| Male | 106 | 45 | 151 |
| Ethnicity (NIH/OMB)(Participants) | Arimoclomol (up to 76 Weeks) | Placebo (up to 76 Weeks) | Total |
|---|---|---|---|
| Hispanic or Latino | 13 | 7 | 20 |
| Not Hispanic or Latino | 132 | 64 | 196 |
| Unknown or Not Reported | 15 | 8 | 23 |
| Race (NIH/OMB)(Participants) | Arimoclomol (up to 76 Weeks) | Placebo (up to 76 Weeks) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 1 | 2 |
| White | 136 | 66 | 202 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 23 | 11 | 34 |
| Revised ALS Functional Rating Scale (ALSFRS-R)(units on a scale) | Arimoclomol (up to 76 Weeks) | Placebo (up to 76 Weeks) | Total |
|---|---|---|---|
| Mean | 40.6 ± 3.93 | 40.2 ± 3.65 | 40.5 ± 3.83 |
| Percent (%) Predicted Slow Vital Capacity (SVC)(percent (%) predicted SVC) | Arimoclomol (up to 76 Weeks) | Placebo (up to 76 Weeks) | Total |
|---|---|---|---|
| Mean | 95.8 ± 15.98 | 98.1 ± 14.78 | 96.5 ± 15.60 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2018 to primary completion in Dec 2020, 28 months.
Results were first posted in Aug 2023, 2 years 8 months after primary completion.
Of 24 phase 3 interventional studies under Amyotrophic Lateral Sclerosis, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 60. This study's 28 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Arimoclomol
Amyotrophic Lateral Sclerosis →
ZevraDenmark